Hemoglobin binds to oxygen, enabling red blood cells to supply oxygenated blood throughout the body. Women of child-bearing age, children, and people with poor diet are most susceptible to the disease. Most cases of iron-deficiency anemia are mild, but if not treated can cause problems like an irregular heartbeat, pregnancy complications, and delayed growth in infants and children that could affect their cognitive development and their behavior. Signs and symptoms
Symptoms of iron deficiency can occur even before the condition has progressed to iron deficiency anemia. Symptoms of iron deficiency are not unique to iron deficiency (i.e. not pathognomonic). Iron is needed for many enzymes to function normally, so a wide range of symptoms may eventually emerge, either as the secondary result of the anemia, or as other primary results of iron deficiency. Symptoms of iron deficiency include:
fatigue
dizziness/lightheadedness
pallor
hair loss
twitches
irritability
weakness
pica
brittle or grooved nails
hair thinning
Plummer–Vinson syndrome: painful atrophy of the mucous membrane covering the tongue, the pharynx and the esophagus
impaired immune function
pagophagia
restless legs syndromeContinued iron deficiency may progress to anemia and worsening fatigue. Thrombocytosis, or an elevated platelet count, can also result. A lack of sufficient iron levels in the blood is one reason that some people cannot donate blood. Signs and symptoms in children
pale skin
fatigue
slowed growth and development
poor appetite
decrease in the size of testes
behavioral problems
abnormal rapid breathing
frequent infection

Iron requirements in young children to teenagers
Causes
blood loss (hemoglobin contains iron)
donation
excessive menstrual bleeding
non-menstrual bleeding
bleeding from the gastrointestinal tract (anus) (ulcers, hemorrhoids, ulcerative colitis, stomach or colon cancer, etc.)
Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushings disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. The most common side effects include hyperglycaemia (high blood sugar levels), diabetes, diarrhoea, abdominal pain (stomach ache), nausea (feeling sick), cholelithiasis (gallstones), injection site reactions, and tiredness.Pasireotide was approved for Cushings disease by the European Medicines Agency (EMA) in April 2012  and by the U.S. Food and Drug Administration (FDA) in December 2012.Pasireotide LAR (the long-acting-release formulation) was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMA in September 2014. References
External links
"Pasireotide". Drug Information Portal. U.S. National Library of Medicine.